Cited by 1,490Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

Open access

Herbst, Roy S., Prager, Diane, Hermann, Robert, Fehrenbacher, Lou, Johnson, Bruce E., Sandler, Alan, Kris, Mark G., Tran, Hai T., Klein, Pam, Li, Xin, Ramies, David, Johnson, David H., Miller, Vincent A.·2005·Journal of Clinical Oncology

DOI 10.1200/jco.2005.02.840

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients with non-small-cell lung cancer (NSCLC). Erlotinib was combined with chemotherapy to determine if it could improve the outcome of patients with NSCLC. PATIENTS AND METHODS: TRIBUTE randomly assigned patients with good performance status and previously untreated advanced (stage IIIB/IV) NSCLC to erlotinib 150 mg/d or placebo combined with up to six cycles of carboplatin and paclitaxel, followed by maintenance monotherapy with erlotinib. Random assignment was stratified by stage, weight loss in the previous 6 months, measurable disease, and treatment center. The primary end point was overall survival (OS). Secondary end points included time to progression (TTP), objective response (OR), and duration of response. RESULTS: There were 1,059 assessable patients (526 erlotinib; 533 placebo). Median survival for patients treated with erlotinib was 10.6 v 10.5 months for placebo (hazard ratio, 0.99; 95% CI, 0.86 to 1.16; P = .95). There was no difference in OR or median TTP. Patients who reported never smoking (72 erlotinib; 44 placebo) experienced improved OS in the erlotinib arm (22.5 v 10.1 months for placebo), though no other prespecified factors showed an advantage in OS with erlotinib. Erlotinib and placebo arms were equivalent in adverse events (except rash and diarrhea). CONCLUSION: Erlotinib with concurrent carboplatin and paclitaxel did not confer a survival advantage over carboplatin and paclitaxel alone in patients with previously untreated advanced NSCLC. Never smokers treated with erlotinib and chemotherapy seemed to experience an improvement in survival and will undergo further investigation in future randomized trials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.02.840

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Cancer burden in the year 2000. The global picture
Parkin, D. M., Bray, F. I., & Devesa, S. S. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00267-2 · Cited by 2,169
DECLARATION OF HELSINKI.
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069

Show all 25 references

Sorted by citations

Items 801–900 of 1,000

Cancer of the Lung
Horn, L., Eisenberg, R., Gius, D. R., Kimmelshue, K. N., Massion, P. P., Putnam, J. B., Robinson, C. G., & Carbone, D. P. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00072-2 · Cited by 16
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues
Bencardino, K. B., Manzoni, M., Delfanti, S., Riccardi, A., Danova, M., & Corazza, G. R. (2007) · Internal and Emergency Medicine · doi:10.1007/s11739-007-0002-5 · Cited by 16
Small Molecule Signal Transduction Inhibitors for the Treatment of Solid Tumors
Leary, A. F., & Johnston, S. R. D. (2007) · Cancer Investigation · doi:10.1080/07357900701259694 · Cited by 16
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC
Michael, M., White, S. C., Abdi, E. A., Nott, L. M., Clingan, P., Zimet, A. S., Button, P., Gregory, D., Solomon, B., Dobrovic, A., et al. (2014) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12178 · Cited by 15
EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis
Xu, F., Tian, Y., Huang, Y., Zhang, L.-L., Guo, Z.-Z., Huang, J., & Lin, T.-Y. (2011) · 癌症：英文版 · doi:10.5732/cjc.011.10107 · Cited by 15
Integration of EGFR Inhibitors and Conventional Chemotherapy in the Treatment of Non–Small-cell Lung Cancer
Pennell, N. A. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.03.029 · Cited by 15
The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients
Kruser, T. J., Traynor, A. M., & Wheeler, D. L. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.550873 · Cited by 15
Lung Cancer in 2013: State of the Art Therapy for Metastatic Disease
Shepherd, F. A., Bunn, P. A., & Paz-Ares, L. G. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.339 · Cited by 17
Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence
Carlson, J. J. (2009) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.09.49 · Cited by 15
Sufficiency of Single‐Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib
Selaru, P., Tang, Y., Huang, B., Polli, A., Wilner, K. D., Donnelly, E. T., & Cohen, D. P. (2016) · Clinical and Translational Science · doi:10.1111/cts.12388 · Cited by 16
A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer
Hwang, I. G., Jang, J.-S., Oh, S. Y., Lee, S., Kwon, H. C., Lee, G. W., Go, S., Kang, M. H., Cha, Y. J., & Kang, J. H. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9792-z · Cited by 15
Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer
Iwama, E., Nakanishi, Y., & Okamoto, I. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1432356 · Cited by 15
Three cases of severe hepatic impairment caused by erlotinib
Huang, Y., An, S., Chen, Z., & Wu, Y.-L. L. C. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03459.x · Cited by 15
Solubility of Two Polymorphs of Erlotinib Hydrochloride in Isopropanol and Acetone from (273.15 to 303.15) K
Lü, J., Zhan, X., Chen, L., Zhang, L., & Mao, S. (2014) · Journal of Chemical & Engineering Data · doi:10.1021/je500482k · Cited by 15
Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer
Dancey, J. E. (2007) · Drugs · doi:10.2165/00003495-200767080-00003 · Cited by 15
Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study.
Choi, D. R., Lee, K. H., Choi, C., Kim, S., Suh, C., & Lee, J. (2011) · PubMed · Cited by 14
Cytokine and Epigenetic Regulation of Programmed Death-Ligand 1 in Stem Cell Differentiation and Cancer Cell Plasticity
Kuo, M.-H., Chen, P., Yang, Y.-P., Zheng, M., Miao, C., Wen, K., Chang, K.-M., Chou, S., Wang, M., Chiou, S., et al. (2021) · Stem Cells · doi:10.1002/stem.3429 · Cited by 14
Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC).
Shash, E., Peccatori, F. A., & Azim, H. A. (2011) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.12.05 · Cited by 14
Biomarker Analysis for Oncology
Ma, Y., & Gamagedara, S. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.60 · Cited by 14
A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
Lee, C., Sharma, S., Miao, E., Mensah, C., Sullivan, K. M., & Seetharamu, N. (2020) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s258444 · Cited by 15
Erlotinib
Steins, M. B., Thomas, M., & Geißler, M. (2014) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-54490-3_6 · Cited by 14
Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380
Huang, X., Cao, M., Wang, L., Wu, S., Liu, X., Li, H., Zhang, H., Wang, R., Sun, X., Wei, C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2814 · Cited by 14
Current and emerging therapies for patients with advanced non-small-cell lung cancer
Sheth, S. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090457 · Cited by 14
Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non–Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial
Juan, Ó., Aparisi, F., Sánchez-Hernández, A., Muñoz-Langa, J., Esquerdo, G., García-Sánchez, J., López, A., Garde, J., & Giner, V. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.11.006 · Cited by 14
Novel biomarkers of metastatic cancer
Dawood, S. S. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.35 · Cited by 14
Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
Wang, Y., Wang, M., Wang, Q., Geng, Z., & Sun, M. (2017) · Oncotarget · doi:10.18632/oncotarget.14707 · Cited by 15
Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma
Saigal, B., Glisson, B. S., & Johnson, F. M. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282fc46c4 · Cited by 14
SELECTIVE TARGETING OF THE TUMOUR VASCULATURE*
Chan, L. S., Daruwalla, J., & Christophi, C. (2008) · ANZ Journal of Surgery · doi:10.1111/j.1445-2197.2008.04712.x · Cited by 14
A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer
Robert, F., Harper, K., Ackerman, J., & Gupta, S. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1026-5 · Cited by 14
Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer
Toschi, L., Cappuzzo, F., & Janne, P. A. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm311 · Cited by 14
Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Basic Science Discovery with Immediate Clinical Impact
Dowell, J. E., Caplan, N. M., & Palmer, B. F. (2006) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200603000-00006 · Cited by 14
EGF receptor in lung cancer: a successful story of targeted therapy
Domingo, G. C., Perez, C. A., Velez, M., Cudris, J., Raez, L. E., & Santos, E. S. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.141 · Cited by 13
Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease
Kim, Y. H., Fukuhara, A., & Mishima, M. (2011) · Case Reports in Oncology · doi:10.1159/000332758 · Cited by 13
Sequence-Dependent Antiproliferative Effects of Gefitinib and Docetaxel on Non-Small Cell Lung Cancer (NSCLC) Cells and the Possible Mechanism
Chen, B., Zheng, J., Zeng, Y., Li, B., Xie, B., Zheng, J., Zhou, J., & Zhang, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114074 · Cited by 13
Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients
Pircher, A., Ploner, F., Popper, H., & Hilbe, W. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.01.017 · Cited by 13
A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond
Reck, M. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.63 · Cited by 14
Impact Analysis of miR-1253 on Lung Cancer Progression Through Targeted Regulation of ANXA3
Liu, Q., Wang, S., Pei, G., Yang, Y., Min, X., Huang, Y., & Liu, J. (2021) · Cancer Management and Research · doi:10.2147/cmar.s251679 · Cited by 13
Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence
Ao, L., Fang, S., Zhang, K., Gao, Y., Cui, J., Jia, W., Shan, Y., Zhang, J., Wang, G., Liu, J., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02369-3 · Cited by 13
Erlotinib-induced Hepatotoxicity—Clinical Presentation and Successful Management: A Case Report
Arora, A. (2011) · Journal of Clinical and Experimental Hepatology · doi:10.1016/s0973-6883(11)60112-6 · Cited by 13
Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents
Visentin, M., Biason, P., & Toffoli, G. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.05.005 · Cited by 13
Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial
Lee, K. H., Lee, J. S., Wang, J., Hsia, T., Wang, X., Kim, J.-S., & Orlando, M. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2014.051 · Cited by 13
Updates in non-small cell lung cancer - insights from the 2009 45th annual meeting of the American Society of Clinical Oncology
Mirshahidi, H., & Hsueh, C.-T. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-18 · Cited by 13
Erlotinib in non-small-cell lung cancer
Gridelli, C., Rossi, A., Maione, P., Colantuoni, G., Gaizo, F. D., Ferrara, C., Nicolella, D., & Guerriero, C. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.15.2579 · Cited by 13
An Economic Model to Value Companion Diagnostics in Non-Small-Cell Lung Cancer
Lieberthal, R. D., Dudash, K., Axelrod, R. S., & Goldfarb, N. I. (2013) · Personalized Medicine · doi:10.2217/pme.13.7 · Cited by 13
Saudi lung cancer management guidelines 2017
Jazieh, A. R., Kattan, K. A., Bamousa, A., Olayan, A. A., Abdelwarith, A., Ansari, J., Al-Twairqi, A., Alfayea, T. M., Saleh, K. A., Husaini, H. A., et al. (2017) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_92_17 · Cited by 12
The role of gefitinib in the management of Asian patients with non-small cell lung cancer
Chang, A. Y. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.3.401 · Cited by 13
EGFR-directed therapies to treat non-small-cell lung cancer
Ho, C., & Laskin, J. J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903066772 · Cited by 13
Erlotinib in non-small cell lung cancer: a review
Blackhall, F. H., Rehman, S., & Thatcher, N. J. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.6.995 · Cited by 13
Current and emerging medical treatments for non–small cell lung cancer: A primer for pulmonologists
Mazzone, P. J., & Mekhail, T. M. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2011.10.016 · Cited by 15
From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer.
Weiss, G. J., Bunn, P. A., & Camidge, D. R. (2006) · PubMed · Cited by 13
Epidermal growth factor receptor as a major anticancer drug target
Caponigro, F., Milano, A., Ottaiano, A., & Iaffaioli, R. V. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.6.877 · Cited by 13
Targeted Therapies for Non-Small Cell Lung Cancer
Παπαέτης, Γ., Roussos, C., & Syrigos, K. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207781757079 · Cited by 13
Future Directions in the Second-Line Treatment of Non–Small Cell Lung Cancer
Rosell, R., Cecere, F. L., Cognetti, F., Cuello, M. A., Sánchez, J. M., Tarón, M., Reguart, N., & Jablons, D. M. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.12.002 · Cited by 13
50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic
Naidoo, J., Niroula, A., Uprety, D., Smeltzer, M. P., Geissen, N. M., Osarogiagbon, R. U., Mino-Kenudson, M. A., Yatabe, Y., Higgins, K. A., Desai, A. P., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.06.028 · Cited by 13
The Role of Cetuximab in the Management of Non–Small-Cell Lung Cancer
Owonikoko, T. K., Sun, S., & Ramalingam, S. S. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.031 · Cited by 12
Induction Pemetrexed and Cisplatin Followed by Maintenance Pemetrexed Versus Carboplatin Plus Paclitaxel Plus Bevacizumab Followed by Maintenance Bevacizumab: A Quality of Life–Oriented Randomized Phase III Study in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer (ERACLE)
Galetta, D., Pisconti, S., Cinieri, S., Pappagallo, G. L., Gebbia, V., Borsellino, N., Maiello, E., Rinaldi, A., Montrone, M., Rizzo, P., et al. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.06.006 · Cited by 12
Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer
Mok, T. S. K., Geater, S. L., Iannotti, N. O., Thongprasert, S., Spira, A. I., Smith, D. C., Lee, V. H.-F., Lim, W., Reyderman, L., Wang, B., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu174 · Cited by 12
The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis
Wang, L., Li, Y., Li, L., Wu, Z., Yang, D., Ma, H., & Wang, D. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s157755 · Cited by 12
Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress
Castellanos, E. H., & Horn, L. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0365-1 · Cited by 12
A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada
Hirsh, V., Melosky, B. L., Goss, G. D., Morris, D. G., & Morzycki, W. (2012) · Current Oncology · doi:10.3747/co.19.1018 · Cited by 12
Clinical Features Reflect Exon Sites of EGFR Mutations in Patients with Resected Non-Small-Cell Lung Cancer
Na, I. I., Rho, J. K., Choi, Y. J., Kim, C. H., Koh, J. S., Ryoo, B., Yang, S. H., & Lee, J. C. (2007) · Journal of Korean Medical Science · doi:10.3346/jkms.2007.22.3.393 · Cited by 12
Tailoring Tyrosine Kinase Inhibitors to Fit the Lung Cancer Genome
Looyenga, B. D., Cherni, I., MacKeigan, J. P., & Weiss, G. J. (2011) · Translational Oncology · doi:10.1593/tlo.10241 · Cited by 12
Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs
Huang, J.-J., Li, Z., Huang, Y., Huang, Y., Tian, Y., He, X.-X., Xiao, J., & Lin, T.-Y. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9558-4 · Cited by 12
Meta-analysis of Seven Randomized Control Trials to Assess the Efficacy and Toxicity of Combining EGFR-TKI with Chemotherapy for Patients with Advanced NSCLC who Failed First-Line Treatment
Xiao, B., Yang, J., Dong, J.-X., Ji, Z.-S., Si, H., Wang, W., & Rong-qing, H. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.7.2915 · Cited by 12
Reducing Tobacco-Related Cancer Incidence and Mortality
Forum, N. C. P., & Board on Health Care Services (2013) · National Academies Press eBooks · doi:10.17226/13495 · Cited by 13
The top 100 cited articles in lung cancer – a bibliometric analysis
Samancı, N. Ş., & Çelik, E. (2020) · Współczesna Onkologia · doi:10.5114/wo.2020.94725 · Cited by 12
Combination Compositions Composed of l-Glutamine and Si-Jun-Zi-Tang Might Be a Preferable Choice for 5-Fluorouracil-Induced Intestinal Mucositis: An Exploration in a Mouse Model
Qu, L., Tan, W., Yang, J., Lai, L., Liu, S., Wu, J., & Zou, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00918 · Cited by 12
The impact of second-line agents on patients’ health-related quality of life in the treatment for non-small cell lung cancer: a systematic review
Ganguli, A. X., Wiegand, P. N., Gao, X. Y., Carter, J. A., Botteman, M. F., & Ray, S. (2012) · Quality of Life Research · doi:10.1007/s11136-012-0229-0 · Cited by 12
Personalized Therapy for Non-Small Cell Lung Cancer: Which Drug for Which Patient?
Villaruz, L. C., & Socinski, M. A. (2011) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2012.01.001 · Cited by 12
Drug Interaction Studies Reveal That Simotinib Upregulates Intestinal Absorption by Increasing the Paracellular Permeability of Intestinal Epithelial Cells
Zhu, Q., Liu, Z., Li, P., & Cheng, Z. (2014) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-13-rg-123 · Cited by 12
Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer
Lin, C., & Yang, C.-H. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0104-2 · Cited by 12
Non-small-cell lung cancer in the elderly
Meriggi, F. A., & Zaniboni, A. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.06.004 · Cited by 12
Targeting novel and established therapies for non-small cell lung cancer
Spicer, J. F., Chowdhury, S., & Harper, P. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.09.001 · Cited by 11
Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer
Sun, K., Wang, X., Zhang, H., Lin, G., & Jiang, R. (2024) · Cancer Control · doi:10.1177/10732748241278039 · Cited by 12
A strategic review of STAT3 signaling inhibition by phytochemicals for cancer prevention and treatment: Advances and insights
Manoharan, S., & Perumal, E. (2024) · Fitoterapia · doi:10.1016/j.fitote.2024.106265 · Cited by 11
EGFR mutations in malignant pleural effusions from lung cancer
Shamblin, C. J., Tanner, N. T., Sanchez, R., Woolworth, J. A., & Silvestri, G. A. (2013) · Current Respiratory Care Reports · doi:10.1007/s13665-013-0041-5 · Cited by 11
Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?
Domvri, K., Bougiouklis, D., Zarogoulidis, P., Porpodis, Κ., Xristoforidis, M., Liaka, A., Eleutheriadou, E., Lampaki, S., Lazaridis, G., Organtzis, J., et al. (2015) · Journal of Cancer · doi:10.7150/jca.11308 · Cited by 11
Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison
Qi, W., Tang, L., He, A., Shen, Z., Lin, F., & Yao, Y. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.675880 · Cited by 11
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI)versusintercalated TKI with chemotherapy forEGFR-mutated nonsmall cell lung cancer
Gijtenbeek, R. G. P., van der Noort, V., Aerts, J. G. J. V., den Brekel, J. A. S.-V., Smit, E. F., Krouwels, F. H., Wilschut, F. A., Hiltermann, T. J. N., Timens, W., Schuuring, E. M. D., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00239-2022 · Cited by 11
Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer
Ricciardi, S. (2010) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s10167 · Cited by 11
Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors
Kotteas, E. A., Charpidou, A. G., & Syrigos, K. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328334da02 · Cited by 11
Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
Gettinger, S. N. (2010) · Biologics · doi:10.2147/btt.s7223 · Cited by 11
Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier
Sangha, R. S., Lara, P. N., Mack, P. C., & Gandara, D. R. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283210489 · Cited by 11
Intermittent Chemotherapy and Erlotinib for Nonsmokers or LightSmokers with Advanced Adenocarcinoma of the Lung: A Phase II Clinical Trial
Zwitter, M., Rajer, M., Kovač, V., Kern, I., Vrankar, M., & Smrdel, U. (2011) · BioMed Research International · doi:10.1155/2011/185646 · Cited by 11
Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials
Qi, W., Fu, S., Zhang, Q., & Guo, X. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.978448 · Cited by 11
A Benefit-Risk Assessment of Erlotinib in Non-Small-Cell Lung Cancer and Pancreatic Cancer
Mountzios, G., & Syrigos, K. (2011) · Drug Safety · doi:10.2165/11586540-000000000-00000 · Cited by 11
Maintenance or Consolidation Therapy for Non–Small-Cell Lung Cancer: A Meta-Analysis Involving 5841 Subjects
Zhang, C., Huang, C., Wang, J., Wang, X., & Li, K. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.01.002 · Cited by 11
Real‐world data in the molecular era—finding the reality in the real world
Dickson, D., & Pfeifer, J. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.300 · Cited by 11
The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib
Zhou, J., Tian, X., Cheng, L., Zhou, Q., Liu, Y., Zhang, Y., Bai, Y., & Ma, H. (2015) · Medicine · doi:10.1097/md.0000000000001719 · Cited by 11
Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
Riess, J. W., & Wakelee, H. A. (2012) · PubMed · Cited by 11
Risk of Severe Rash in Cancer Patients Treated with Egfr Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis
Zhang, X., Ran, Y.-G., & Wang, K. (2016) · Future Oncology · doi:10.2217/fon-2016-0180 · Cited by 11
Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer
Rossi, A., Salvia, A. L., & Maïo, M. D. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1290526 · Cited by 11
Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors
Lin, L., Zhao, J., Kong, N., He, Y., Hu, J., Huang, F., Han, J., & Cao, X. (2017) · Oncotarget · doi:10.18632/oncotarget.18283 · Cited by 11
Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis
Aguilar, K. M., Winfree, K. B., Muehlenbein, C. E., Zhu, Y. E., Wilson, T., Wetmore, S., & Nadler, E. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0811-0 · Cited by 11
Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients
Kwan, T. Y., & Chowdhury, E. H. (2021) · Medicina · doi:10.3390/medicina57111252 · Cited by 10
EGFR genomic alterations in cancer: prognostic and predictive values
Bronte, G. (2009) · Frontiers in Bioscience-Elite · doi:10.2741/296 · Cited by 11
A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors
Chu, Q. S.-C., Sangha, R. S., Hotte, S. J., Sergenson, G., Schnell, D., Chand, V. K., & Hirte, H. W. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0139-9 · Cited by 11
The Marriage of Growth Factor Inhibitors and Chemotherapy: Bliss or Bust?
Staal, S. P., O’Connell, M. J., & Allegra, C. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.3224 · Cited by 11
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy
Giaccone, G., Iacona, R. B., Fandi, A., Janas, M. S., Ochs, J. S., Herbst, R. S., & Johnson, D. H. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0466-3 · Cited by 11
The Translational Research Working Group Developmental Pathway for Anticancer Agents (Drugs or Biologics)
Schilsky, R. L., Gordon, G., Gilmer, T. M., Courtneidge, S. A., Matrisian, L. M., Grad, O., & Nelson, W. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1265 · Cited by 11

Authors: Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., Ramies, D., Johnson, D. H., & Miller, V. A.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
ORCID: Herbst, Roy S.
Johnson, Bruce E.
Sandler, Alan
Kris, Mark G.
Tran, Hai T.
Li, Xin
Ramies, David
Johnson, David H.
Miller, Vincent A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2005-09-01
Volume: 23
Issue: 25
Pages: 5892-5899
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.02.840
OpenAlex: W2162724777
Cited by: 1,490
References: 25
Citations by year: 2026: 9 · 2025: 4 · 2024: 7 · 2023: 11 · 2022: 19 · 2021: 24 · 2020: 29 · 2019: 22 · 2018: 32 · 2017: 48 · 2016: 56 · 2015: 83 · 2014: 79 · 2013: 122 · 2012: 96
FWCI: 123.05
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: erlotinib, carboplatin, paclitaxel, non-small cell lung cancer, EGFR tyrosine kinase inhibitors, combination chemotherapy, never smokers, overall survival, time to progression, objective response, maintenance therapy
MeSH terms: Erlotinib Hydrochloride, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Placebos, Quinazolines, Survival Analysis, Carboplatin, Paclitaxel, Disease Progression, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks